- Delic Holdings Corp. (the “company” or “Delic”) reported Q2 revenues of $149,290 while realizing a strong gross profit margin of 87%
- The company has recently broadened its business verticals through the acquisition of Homestead, a psychedelic media distributor, and Ketamine Infusion Centers LLC, one of the largest chains of ketamine clinics in the U.S.
Delic Holdings (CSE: DELC) (OTCQB: DELCF), a leading psychedelic wellness platform committed to bringing science-backed benefits to its many stakeholders, has recently published its second quarter results for the 2021 fiscal year. The company reported Q2 revenues of $149,290. Delic also reported second quarter gross profits of $130,129, resulting in an impressive 87% gross profit margin (https://ibn.fm/DZ5QQ).
The company owns and operates a self-sustaining ecosystem of businesses in the psychedelic space consisting of media, science and health business verticals. Delic has been particularly active on the mergers and acquisition front over the last several months in a bid to further broaden the company’s business horizons. On June 30, 2021, the company acquired Ketamine Infusion Centers LLC (“KIC”), one of the largest ketamine clinics in the United States, for gross consideration of $3,040,312. In March, Delic successfully completed the acquisition of the brand and intellectual property of Homestead, a legacy counterculture distributor of psychedelic media and creator of one of the first self-contained mushroom grow kits.
Moving forward, the Delic ecosystem will be centered across three primary pillars, namely — media, health and science. On the media front, the company will seek to nurture new audiences and educate the public on the latest developments within the psychedelic sector through a variety of digital platforms, including Delic’s Reality Sandwich digital magazine; Meet Delic, the first-ever psychedelic wellness summit to be based in Las Vegas and which attracted over 2,000 live attendees at its inaugural event; and Delic Radio, an online podcast program boasting over 43 episodes and upwards of 100 thousand total streams to date.
Delic’s focus within the health sphere will be centered around the Ketamine Infusion Centers, an Arizona-based clinical chain with three ketamine clinics located in Bakersfield, California, and Phoenix, Arizona. The clinics, which have cumulatively overseen 4,000+ treatments delivered to date, have plans to scale and operate over 20 clinics, with a plan to operate 10 more clinics over the coming 18 months.
On its Sept. 20 press release, Delic announced a merger with Arizona-based ketamine infusion clinic company Ketamine Wellness Centers Inc. KWC operates 10 clinics across multiple states, cementing Delic’s position as the largest ketamine health provider and psychedelic wellness chain in the country.
“The Delic team is committed to making psychedelic wellness accessible to the masses, and with this chain of clinics and upcoming acquisitions, we are making that vision possible,” stated Matt Stang, Founder and CEO (https://ibn.fm/GIz2h).
Lastly, the company’s science business will be focused around developing IP and advanced extraction and testing facilities, which form the backbone of the legal market. The company will center their efforts through Delic Labs, a licensed cannabis and psilocybin research laboratory based in Vancouver and the only entity licensed by Health Canada to exclusively focus on research and development of psilocybin vaporization technology.
North America is currently blazing the path in advancing the psychedelic industry through a variety of forward-looking research projects, at a time when psychedelics are increasingly becoming accepted globally on the basis of their therapeutic, medical, and recreational use. With 32 million people in the U.S., or 17% of all American adults aged 21 to 64, having used psychedelics at least once, the industry seems to be well on its way to mainstream acceptance (https://ibn.fm/XtiVY). Through their various initiatives and three core business verticals, Delic Corp. is well positioned to capitalize on the sector’s continued growth trajectory.
For more information, visit the company’s website at www.DelicCorp.com.
NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at https://ibn.fm/DELCF
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire is part of the InvestorBrandNetwork.